View Archive »
About The Cover
The cover for issue 10 of Oncotarget features Figure 3, "Overall survival (OS) for high (red) versus low (black) risk groups in the (A) OSU, (B) TCGA, and (C) SNU resected cohorts," by Wolfe, et al.
Table of Contents
MicroRNA (miR) dysregulation during Helicobacter pylori-induced gastric inflammation and cancer development: critical importance of miR-155
MicroRNA (miR) dysregulation during Helicobacter pylori-induced gastric inflammation and cancer development: critical importance of miR-155 |
https://doi.org/10.18632/oncotarget.27520
Christian Prinz,
and David Weber
|
894-904 |
DNA methylation of MMPs and TIMPs in atherothrombosis process in carotid plaques and blood tissues
DNA methylation of MMPs and TIMPs in atherothrombosis process in carotid plaques and blood tissues |
https://doi.org/10.18632/oncotarget.27469
Cristina Gallego-Fabrega,
Natalia Cullell,
Carolina Soriano-Tárraga,
Caty Carrera,
Nuria P. Torres-Aguila,
Elena Muiño,
Jara Cárcel-Márquez,
Manuel Castro de Moura,
Alba Fernández-Sanlés,
Manel Esteller,
Roberto Elosua,
Jordi Jiménez-Conde,
Jaume Roquer,
Joan Montaner,
Jerzy Krupinski,
and Israel Fernandez-Cadenas
|
905-912 |
A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection
A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection |
https://doi.org/10.18632/oncotarget.27496
Adam R. Wolfe,
Patrick Wald,
Amy Webb,
Nikhil Sebastian,
Steve Walston,
Ryan Robb,
Wei Chen,
Marall Vedaie,
Mary Dillhoff,
Wendy L. Frankel,
Wooil Kwon,
Jin-Young Jang,
and Terence M. Williams
|
913-923 |
Prognostic and predictive factors in pancreatic cancer
Prognostic and predictive factors in pancreatic cancer |
https://doi.org/10.18632/oncotarget.27518
Emanuela Dell’Aquila,
Claudia Angela Maria Fulgenzi,
Alessandro Minelli,
Fabrizio Citarella,
Marco Stellato,
Francesco Pantano,
Marco Russano,
Maria Concetta Cursano,
Andrea Napolitano,
Tea Zeppola,
Bruno Vincenzi,
Giuseppe Tonini,
and Daniele Santini
|
924-941 |
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)* |
https://doi.org/10.18632/oncotarget.27512
David M. Goldenberg,
Thomas M. Cardillo,
Serengulam V. Govindan,
Edmund A. Rossi,
and Robert M. Sharkey
|
942-942 |